EBNA1 may prolong G2/M phase and sensitizes HER2/neu-overexpressing ovarian cells to both topoisomerase II-targeting and paclitaxel drugs

doi:10.1016/S0006-291X(03)01235-X

淡江大學機構典藏 > 理學院 > 化學學系暨研究所 > 期刊論文 > Item 987654321/61569

請使用永久網址來引用或連結此文件: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/61569

題名:	EBNA1 may prolong G2/M phase and sensitizes HER2/neu-overexpressing ovarian cells to both topoisomerase II-targeting and paclitaxel drugs
作者:	Chuang, TC;Lee, YJ;Liu, JY;Lin, YS;Lee, JW;Wang, V;Law, SL;Kao, Ming-Ching
貢獻者:	淡江大學化學學系
關鍵詞:	HER2/neu;EBNA1;Tumorigenicity;Ovarian cancer
日期:	2003-08
上傳時間:	2013-05-31 11:35:07 (UTC+8)
出版者:	Maryland Heights: Academic Press
摘要:	We have shown previously that the Epstein-Barr virus nuclear antigen-1 (EBNA1) can act as a transforming suppressor in the HER2/neu-overexpressing ovarian cancer cells. In the present study, by using flow cytometric analysis, we demonstrate that EBNA1 could prolong G(2)/M phase and sensitize to Taxol-induced apoptosis in the EBNA1-expressing ovarian cancer cell stable transfectants. In addition, EBNA1 could also significantly increase topoisomerase IIalpha protein expression, indicating that the up-regulation of topoisomerase IIalpha may be one of the mechanisms by which EBNA1 enhances the sensitivity of ovarian cancer cells to topoisomerase II-targeting anticancer drugs, such as VP-16 and Adriamycin. These data suggest that EBNA1 not only prolongs cell cycle at G(2)/M phase and up-regulates topoisomerase IIalpha expression in HER2/neu-overexpressing ovarian cancer cells, but also increases cellular apoptosis through sensitization of cancer cells to topoisomerase II-directing anticancer drugs.
關聯:	Biochemical and Biophysical Research Communications 307(3), pp.653-659
DOI:	10.1016/S0006-291X(03)01235-X
顯示於類別:	[化學學系暨研究所] 期刊論文

文件中的檔案:

檔案	大小	格式	瀏覽次數
index.html	0Kb	HTML	38	檢視/開啟

在機構典藏中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....